Welcome to our dedicated page for Establishment Labs Holdings news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Holdings stock.
Establishment Labs Holdings Inc. develops and markets medical technology for women’s health, principally breast aesthetics and reconstruction. The company’s recurring news covers Motiva implants and related minimally invasive platform activity, global product adoption, U.S. and outside-the-U.S. commercialization, and sales channels serving distributors, physicians, hospitals, and clinics.
Updates also include quarterly and annual financial results, revenue guidance, operating expense leverage, adjusted EBITDA commentary, credit-facility refinancing, leadership changes, and health care conference participation. Product and market updates commonly center on the Motiva portfolio, silicone-filled breast and body-shaping implants, and expansion across Europe, Latin America, Asia-Pacific/Middle East, and other markets.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will release its financial results for the quarter ending March 31, 2023, post-market on May 8, 2023. A conference call to discuss the results is scheduled for 4:30 PM ET on the same day. Interested participants can join the call by dialing (877) 407-8037 for U.S. participants or (201) 689-8037 for international callers. The event will also be available via live and archived webcast on the Establishment Labs investor relations webpage.
Establishment Labs specializes in medical technology focused on women's health, offering products like the Motiva® breast devices, which are backed by over 200 patents. The company operates two manufacturing facilities in Costa Rica, adhering to strict regulatory standards.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has announced a public offering of 1,100,000 common shares priced at $71.50, with gross proceeds estimated at $78.7 million. The offering, scheduled to close on April 27, 2023, includes a 30-day option for underwriters to purchase an additional 165,000 shares. Proceeds from the offering will be allocated for general corporate purposes, including sales and marketing, research and development, and working capital. Jefferies, J.P. Morgan, Citigroup, and TD Cowen are the joint book-running managers for this offering, which was filed under a prospectus supplement dated April 24, 2023.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has initiated a public offering of its common shares, with a possible additional 15% for underwriters. The offering's proceeds will fund general corporate needs, including sales, marketing, research, and working capital. Market conditions will dictate the offering's completion and terms. Jefferies, J.P. Morgan, Citigroup, and TD Cowen are the joint book-running managers, while BTIG acts as co-manager. The offering materials are detailed in a prospectus supplement filed under the company's existing shelf registration.
This action reflects Establishment Labs' commitment to advancing women’s health through its innovative Femtech solutions, including the Motiva® devices. These devices have redefined safety and satisfaction standards in 85 countries.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced preliminary unaudited financial results for Q1 2023, reporting revenue of approximately $46.5 million, a significant increase from $38.5 million in Q1 2022. The company's cash balance is projected at $42.8 million, while total debt, including principal and interest, is expected to be around $184.0 million. These preliminary results are subject to change pending audits. Establishment Labs focuses on women’s health and offers innovative solutions in breast aesthetics and reconstruction, with a strong portfolio including the Motiva® devices.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) presented a three-year follow-up report from the Motiva US IDE Study at The Aesthetic Meeting 2023 in Miami, Florida. The study involved 451 primary augmentation patients with a compliance rate of 92.4%. Key findings showed low complication rates: capsular contracture at 0.5%, rupture at 0.6%, and infection at 0.9%. The overall complication rate was reported at 8.4%. Dr. Caroline Glicksman, the study's Medical Director, noted the consistent clinical outcomes, highlighting the performance of Motiva implants and signaling hope for eventual FDA approval. The Motiva device remains under investigation and is not FDA-approved for commercial sale in the United States.